Feng Jiao

Feng Jiao

Auto-generated profile, based on publicly available information

Feng Jiao

Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
HHHai Hu
Hai Hu
JHJun-Jie Hang
Jun-Jie Hang
THTing Han
Ting Han
MZMeng Zhuo
Meng Zhuo
FJFeng Jiao
Feng Jiao
LWLi-Wei Wang
Li-Wei Wang

28 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HHHai Hu
Hai Hu
THTing Han
Ting Han
MZMeng Zhuo
Meng Zhuo
LWLei-Lei Wu
Lei-Lei Wu
CYCuncun Yuan
Cuncun Yuan
LWLi-Wei Wang
Li-Wei Wang
Cyclooxygenase-2 (COX-2) was stated to be overexpression in various human malignancies associating with angiogenesis, metastasis and chemoresistence. Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease displaying many of these characteristics. A common abnormality of PDAC is overexpression of specificity protein-1 (Sp1), which was said to correlate with malignant phenotypes of human cancers. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we found that Sp1 expression was positively correlated with that of COX-2 in PDAC, and that the inhibition or overexpression of Sp1 in PDAC cells leads to decreased or elevated COX-2 expression. Luciferase reporter gene and chromatin immunoprecipitation (ChIP) assays revealed that elevated transcription of COX-2 requires Sp1 binding to sequence positions around −245/−240 of COX-2 promoter. Activated epidermal growth factor receptor (EGFR) and downstream p38 mitogen-activated protein kinase (p38-MAPK) were also profoundly altered in PDAC. The inhibition of EGFR/p38-MAPK signaling resulted in reduced Sp1 activation, decreased COX-2 and vascular endothelial growth factor (VEGF) expression. Thus, Sp1 could transcriptionally activate COX-2 expression in a process relies on activated EGFR/p38-MAPK signaling. Finally, we found that the inhibition of COX-2 leads to decreased angiogenesis in a process dependent on VEGF, which link COX-2 to angiogenesis in PDAC.

23 October 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MZMeng Zhuo
Meng Zhuo
CYCuncun Yuan
Cuncun Yuan
THTing Han
Ting Han
JCJiujie Cui
Jiujie Cui
FJFeng Jiao
Feng Jiao
LWLiwei Wang
Liwei Wang
It was demonstrated that long non-coding RNAs occupied an important position in tumor pathogenesis and progression. We have previously found that the metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) promotes cell proliferation and metastases in pancreatic ductal adenocarcinoma (PDAC). The present study was aimed to discuss the underlying mechanisms. Bioinformatics method was used to identify the miRNA target of MALAT-1. Expressions of relative genes were assessed by quantitative real-time PCR and western blotting, respectively. Sulforhodamine B assay and Transwell assay were employed to detect cell proliferation, migration and invasion, respectively. Moreover, RNA immunoprecipitation was performed to determine whether RNA-induced silencing complex contained MALAT-1 and its potential binding miRNA. Luciferase assays was used to confirm potential binding site. Bioinformatics search predicted that miR-200c-3p was a direct target of MALAT-1. Further, we found a reciprocal suppression between MALAT-1 and miR-200c-3p expression. In terms of mechanisms, high MALAT-1 and low miR-200c-3p may form a novel feedback loop. On the one hand, MALAT-1 functioned as a competing endogenous RNA to suppress miR-200c-3p expression, leading to upregulation of ZEB1 expression. On the other hand, miR-200c-3p inhibited the level of MALAT-1 expression was in a way similar to miRNA-mediated downregulation of target genes. Clinical data further indicated that MALAT-1 and ZEB1 expression was negatively correlated with miR-200c-3p transcript level of PDAC tissues. There was a positive correlation between MALAT-1 and ZEB1 level. MALAT-1 (high)/miR-200c-3p (low) correlated with shorter overall survival of PDAC patients. Multivariate analysis revealed that both MALAT-1 and miR-200c-3p levels were independent prognostic factors. Our findings firstly revealed a novel feedback loop between high MALAT-1 and low miR-200c-3p. Targeting the feedback loop between high MALAT-1 and low miR-200c-3p will be a therapeutic strategy for PDAC.

5 April 2016 in Oncotarget
Verified
Journal Article
Open access
HHHai Hu
Hai Hu
JHJunjie Huang
Junjie Huang
THTing Han
Ting Han
MZMeng Zhuo
Meng Zhuo
YZYangyang Zhou
Yangyang Zhou
LWLiwei Wang
Liwei Wang
Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma

1 January 2019
Verified
Journal Article
Closed access
MZMeng Zhuo
Meng Zhuo
CYCuncun Yuan
Cuncun Yuan
THTing Han
Ting Han
HHHai Hu
Hai Hu
JCJiujie Cui
Jiujie Cui
LWLiwei Wang
Liwei Wang

3 October 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
HHHai Hu
Hai Hu
HLHong Li
Hong Li
FJFeng Jiao
Feng Jiao
THTing Han
Ting Han
MZMeng Zhuo
Meng Zhuo
LWLiwei Wang
Liwei Wang
Multiple primary cancers (MPC) have been identified as two or more cancers without any subordinate relationship that occur either simultaneously or metachronously in the same or different organs of an individual. Lynch syndrome is an autosomal dominant genetic disorder that increases the risk of many types of cancers. Lynch syndrome patients who suffer more than two cancers can also be considered as MPC; patients of this kind provide unique resources to learn how genetic mutation causes MPC in different tissues. We performed a whole genome sequencing on blood cells and two tumor samples of a Lynch syndrome patient who was diagnosed with five primary cancers. The mutational landscape of the tumors, including somatic point mutations and copy number alternations, was characterized. We also compared Lynch syndrome with sporadic cancers and proposed a model to illustrate the mutational process by which Lynch syndrome progresses to MPC. We revealed a novel pathologic mutation on the MSH2 gene (G504 splicing) that associates with Lynch syndrome. Systematical comparison of the mutation landscape revealed that multiple cancers in the proband were evolutionarily independent. Integrative analysis showed that truncating mutations of DNA mismatch repair (MMR) genes were significantly enriched in the patient. A mutation progress model that included germline mutations of MMR genes, double hits of MMR system, mutations in tissue-specific driver genes, and rapid accumulation of additional passenger mutations was proposed to illustrate how MPC occurs in Lynch syndrome patients. Our findings demonstrate that both germline and somatic alterations are driving forces of carcinogenesis, which may resolve the carcinogenic theory of Lynch syndrome.